Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

45.40USD
23 Feb 2017
Change (% chg)

$0.39 (+0.87%)
Prev Close
$45.01
Open
$45.02
Day's High
$45.51
Day's Low
$44.85
Volume
9,459,424
Avg. Vol
9,046,549
52-wk High
$45.79
52-wk Low
$36.76

Latest Key Developments (Source: Significant Developments)

Terumo Corp looks to purchase portion of Abbott Laboratories' medical device business - Nikkei
Thursday, 29 Sep 2016 01:16pm EDT 

Nikkei: Terumo Corp is looking to purchase a portion of Abbott Laboratories' medical device business - Nikkei . Abbott has put some operations on auction block, and Terumo Corp has apparently made bid for cardiovascular device segment and other operations - Nikkei .Terumo Corp's potential deal to purchase Abbott Laboratories' medical device business could be worth as much as 150 billion yen - Nikkei.  Full Article

Abbott Laboratories says "Alere’s lawsuit is without merit"
Friday, 26 Aug 2016 12:26pm EDT 

Abbott Laboratories : Abbott Laboratories says "Alere’s lawsuit is without merit" . Compliant with obligations under merger agreement with Alere . "continues to work toward regulatory approvals despite Alere’s nearly six month delay in filing its 2015 10-K" ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

Alere says filed a complaint against Abbott on Aug. 25
Friday, 26 Aug 2016 11:00am EDT 

Alere Inc : Alere issues statement . "on August 25, 2016, Alere filed a complaint against Abbott in Delaware Chancery court" . Says expect redacted version of complaint to be publicly available next week . Expect redacted version of complaint to be publicly available next week .Alere will "compel" Abbott to complete transaction in accordance with its terms.  Full Article

Abbott reports Q2 2016 GAAP earnings per share $0.40 from continuing operations
Wednesday, 20 Jul 2016 07:45am EDT 

Abbott Laboratories : Q2 total diagnostics sales $1,226 million versus $1,177 million last year . Q2 total vascular sales $ 782 million versus. $722 million last year . Excluding impact of Venezuelan operations, emerging market sales would have increased 4.8% on reported basis, 12.4% on operational basis in Q2 . Abbott reports Second-Quarter 2016 results . Q2 adjusted earnings per share $0.55 from continuing operations . Q2 gaap earnings per share $0.40 from continuing operations . Q2 earnings per share view $0.53 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $2.14 to $2.24 from continuing operations . Sees FY 2016 GAAP earnings per share $1.26 to $1.36 from continuing operations . Q2 sales $5.3 billion versus i/b/e/s view $5.24 billion . Q2 total nutrition sales $1,740 million versus. $1,717 million last year . Q2 total pediatric sales $ 972 million versus. $968 million last year . Excluding impact of Venezuelan operations, worldwide nutrition sales would have increased 3.3 percent on reported basis,6.2 percent on operational basis .Fy2016 earnings per share view $2.20, revenue view $20.90 billion -- Thomson Reuters I/B/E/S.  Full Article

St Jude Medical reports Q2 earnings per share $0.83
Wednesday, 20 Jul 2016 07:15am EDT 

St. Jude Medical Inc : Total crm sales were $395 million for q2 of 2016, an 8 percent decline compared with Q2 of 2015 . Qtrly international sales increased 10 percent as reported, or 7 percent on a comparable constant currency basis . St. Jude medical reports second quarter 2016 results . Q2 adjusted earnings per share $1.06 . Q2 earnings per share $0.83 . Q2 sales $1.562 billion versus I/B/E/S view $1.55 billion . Q2 earnings per share view $1.06 -- Thomson Reuters I/B/E/S . Total cardiovascular sales were $319 million for Q2 of 2016, an increase of 1 percent compared to prior year quarter .Due to planned merger with Abbott, St. Jude Medical is withdrawing financial guidance for fiscal year 2016.  Full Article

Abbott Laboratories says U.S. FDA approves Tecnis Symfony intraocular lenses
Friday, 15 Jul 2016 12:49pm EDT 

Abbott Laboratories : FDA approves Tecnis Symfony intraocular lenses, the first and only extended depth of focus lenses for people with cataracts .FDA approval includes a version of lens for people with astigmatism, Tecnis Symfony toric iol.  Full Article

Health Canada approves Abbott's 'Absorb' bioresorbable stent
Thursday, 14 Jul 2016 01:15pm EDT 

Abbott Laboratories : Health Canada approves Abbott's Absorb bioresorbable stent, the first fully dissolving heart stent .Abbott plans to offer the device to Canadian hospitals nationwide starting this summer.  Full Article

St Jude and Abbott Labs receive request for additional information from U.S. FTC
Tuesday, 12 Jul 2016 06:31pm EDT 

St Jude Medical: Abbott labs, st. Jude medical each received request for additional information from u.s. Ftc relating to abbott's potential acquisition of st. Jude medical .Effect of requests, which were issued under hart-scott rodino antitrust improvements act, is to extend waiting period imposed by Hart-Scott-Rodino act.  Full Article

Abbott sets quarterly dividend of $0.26/shr
Friday, 10 Jun 2016 11:05am EDT 

Abbott Laboratories :Sets quarterly dividend of $0.26 per share.  Full Article

Abbott Laboratories to acquire St. Jude medical
Thursday, 28 Apr 2016 06:48am EDT 

Abbott Laboratories:To acquire st. Jude medical.Transaction expected to be accretive to abbott's adjusted earnings per share in first full year after closing and increasing thereafter.Abbott laboratories says st. Jude medical shareholders will receive $46.75 in cash and 0.8708 shares of abbott common stock.Total transaction equity value of $25 billion.Says Abbott intends to fund cash portion of this transaction with medium-and long-term debt.Transaction has been approved by boards of directors of st. Jude medical and abbott.Says st. Jude medical's net debt of approximately $5.7 billion will be assumed or refinanced by abbott.Expects to issue $3 billion of common stock in secondary market to rebalance its capital structure.Combination is anticipated to result in annual pre-tax synergies of $500 million by 2020.Combination is anticipated to result in annual pre-tax synergies of $500 million by 2020.st. Jude medical's net debt of approximately $5.7 billion will be assumed or refinanced by abbott.Says st. Jude medical's net debt of approximately $5.7 billion will be assumed or refinanced by abbott.Evercore is serving as lead financial advisor for abbott with wachtell, lipton, rosen & katz serving as legal counsel.Evercore is serving as lead financial advisor for abbott.Guggenheim securities is acting as financial advisor and gibson, dunn & crutcher llp is serving as legal counsel to st. Jude medical.  Full Article

More From Around the Web

BRIEF-FTC approves final order settling charges for Abbott's deal with St. Jude Medical

* Approved final order settling charges that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would likely be anticompetitive